SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is drawing attention as traders react to a rebound alongside discussion of Midnights mainnet launch and ecosystem developments, including Google Clouds validator role and a reported Coinbase listing. Some see these as signs of growing adoption, while others remain cautious about weak follow-through and selling pressure from token unlocks and airdrops.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs agreement to acquire low-band spectrum and its plans to expand Starlink Mobile have driven concern that it could become a future competitor to T-Mobile and other wireless carriers. Traders debate whether that threat warrants the sharp selloff or is being overstated given the time and infrastructure needed to build a competing network, with many viewing the drop as a buying opportunity.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Firefly shares are drawing attention for continued weakness and underperformance amid a broader pullback in space stocks, with traders debating whether SpaceX is pulling capital away from smaller companies and compressing sector valuations. Some see the decline as excessive given Fireflys contracts and long-term lunar ambitions, while others are frustrated by the stocks inability to hold gains.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Oppenheimers upgrade to Outperform, citing rising contract values and early monetization of agentic AI traffic, is driving attention to Fastly. Traders are broadly reacting bullishly to the growth thesis and rally, while some question how much AI traffic will translate into revenue and warn that the stocks sharp swings may fade.

GEOM maps the world's oil fields, mines, rare earths, and power plants, tracks what is and isn't tokenized, and cryptographically signs every dataset it publishes. Anyone can verify what we said and when. No account, no key, no permission. Sources include the WRI Global Power Plant Database and Global Energy Monitor (CC BY 4.0), attributed in full inside the app. Most of it already exists, spread across filings and terminals no one reads. GEOM gathers it and records where each figure came from.

GEOM

GEOM is drawing attention around its proposed platform for tokenizing oil and mineral assets and royalties, with traders linking its prospects to Greenland Energy (GLND) and anticipating platform or partner developments. Bullish holders see an early real-world-asset opportunity, while skeptics cite the tokens decline, thin liquidity, and uncertainty about execution.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, and Defense. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

A recent pullback has prompted debate, with frustrated traders questioning the weakness while long-term holders point to Rolls-Royces aviation and defense growth prospects, including its India engine ambitions and A350F activity. Speculation about a hyperscaler or SMR-related deal also recurs, but traders acknowledge that a major hyperscaler announcement has not been confirmed.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transoceans new offshore contract and the addition of the Equinor agreement to firm backlog are drawing attention, alongside progress toward its Valaris merger. Traders see growing backlog and high oil prices as bullish, but many are frustrated that RIG has struggled to respond; claims that heavy shorting is suppressing the stock remain speculation.

Robinhood GLD is a tokenized representation of SPDR Gold Shares (GLD) common stock, issued on Robinhood Chain, Robinhood's own blockchain built to bring tokenized real-world assets on-chain. Each token is designed to track the price of the underlying GLD share, giving holders on-chain price exposure to SPDR Gold Shares's stock. The token is freely transferable and composable across the Robinhood Chain ecosystem. It's part of Robinhood's broader initiative to expand access to tokenized U.S. equities via blockchain technology, alongside a wider lineup of tokenized stock tokens launching on the same network.

GoldCoin

Golds recent pullback and choppy rebound dominate discussion, with traders linking pressure on the metal to a stronger dollar, elevated Treasury yields, and hawkish Fed expectations. Some see a potential bottom and point to safe-haven and central-bank demand, while others warn the decline may continue.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgans upcoming third-quarter earnings report is a main focus, with traders also debating a pullback in bank stocks amid rising Treasury yields and concerns about loan growth, deposit costs and credit. Some see the weakness as an opportunity ahead of results, while others remain cautious about pressure on the sector.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A strong, high-volume rally is being attributed by traders to anticipation of founder Patrick Soon-Shiongs Piper Sandler fireside chat and potential trial updates; speculation about a partnership is circulating but remains unconfirmed. The community is also debating whether high short interest could amplify the move, while pointing to ANKTIVA and possible bladder-cancer label expansion as longer-term catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge

Key PointsFCPM III Services B.V. initiated a new position in Damora Therapeutics, adding 2,441,000 shares last quarter; the estimated trade size was $65.63 million (quarterly average pricing...

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Gap Down - Here's Why

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Gap Down - Should You Sell...

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Sees Large Increase in Short Interest

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totaling...

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Upgraded at Royal Bank Of Canada

Royal Bank Of Canada raised shares of Damora Therapeutics, Inc. Common Stock to a "moderate buy" rating in a report on Thursday...

Royal Bank Of Canada Begins Coverage on Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)

Royal Bank Of Canada started coverage on Damora Therapeutics, Inc. Common Stock in a report on Friday. They set an "outperform" rating and a $40.00 price objective for the company...

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the...

What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?

Does Galecto, Inc. (DMRA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Short Interest Update

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) was the target of a large growth in short interest in March. As of March 31st, there was short interest totaling 827,221 shares...

How Much Upside is Left in DAMORA THERAPEU (DMRA)? Wall Street Analysts Think 73.1%

The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in DAMORA THERAPEU (DMRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Up 3.9%  - Here's Why

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Price Up 3.9% - What's Next...

Damora Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Waltham, MA.

Damora Therapeutics Inc.

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$DMRA 
 
Guggenheim went Street-high on a biotech with no clinical data: raised its target to 60 from 40 on Friday, Buy rating, implying about 196% upside off the 20.27 prior close (Benzinga, via Watch List News). Jefferies' 50 was the prior high. 
 
The stock needed the headline. Down 32% in a month and about 40% below its 34.89 52-week high. Friday volume ran 132% above the prior session's on the note. 
 
The drug: DMR-001, a once-monthly subcutaneous antibody against mutCALR for myeloproliferative neoplasms, a 5B-plus market (Seeking Alpha). It is in Phase 1/1b. Incyte's mutCALR competitor is further along. 
 
The cushion: about 540.5M in cash, runway into the second half of 2029. Guggenheim is pricing in a franchise with no human efficacy readout yet.

Feed

News

Sentiment

Earnings

Fundamentals

Info

DMRA Damora Therapeutics Inc.

Fundamentals

Latest DMRA News